D. Boral Capital lowered the firm’s price target on Imunon (IMNN) to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company’s “financial position remains precarious,” contends D. Boral.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- Imunon Announces Warrant Exchange for Equity Securities
- Positive Outlook on Imunon Driven by Advancements in OVATION 3 Study and Strategic Focus on HRD+ Patients
- IMUNON, Inc. Reports Q1 2025 Financial Results and Clinical Progress
- Imunon, Inc. Earnings Call: Clinical Progress Amid Financial Challenges
- Imunon reports Q1 EPS (28c), consensus (36c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue